801-850

Articles Published by the Ocular Immunology and Uveitis Foundation

C. Stephen Foster, M.D.

In Print (801-850)

Previous 50   Next 50

801. Vitreous Evaluation: A Diagnostic Challenge. Mehta M, Rasheed RA, Duker J, Reichel E, Feinberg E, Husain D, Foster CS, Laver NV. Ophthalmology. 2015 Mar;122(3):531-7.

802. Preble J, Foster CS. Uveitic Macular Edema: A Stepladder Treatment Paradigm. Clin Investigation, 2015;5(6):509-17.

803. Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy. Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group. Ophthalmology. 2015 May;122(5):939-48.

804.  Evaluation of the Effect of N-Acetylcysteine on Protein Deposition on Contact Lenses in Patients with the Boston Keratoprosthesis Type I. Kruh JN, Kruh-Garcia NA, Foster CS. J Ocul Pharmacol Ther. 2015 Jul-Aug;31(6):314-22.

805. ‘Approved for use in uveitis’: drug approval for an orphan disease. Metzinger JL, Foster CS.  Expert Opin Orphan Drugs. 2015 Jul;3(7):799-807

806. Are Patients being treated with immunosuppression for ocular inflammatory disease adequately. Cocho L, Swan RT, Foster CS. Expert Rev Ophthalmol. 2015 Aug;10(4):341-50.

807. Efficacy and Safety of Adalimumab for Intraocular Inflammation,. Arcinue CA, Durrani KD, Artornsombudh P, Radwan A, Parikh R, Suelves A, Siddique S, Chang I, Preble J, Foster CS. Orphan Drugs: Research and Reviews. 2015 Aug;5:69-74.

808. Kothari S, Foster CS, Pistilli M, Liesegang TL, Daniel E, Sen HN, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Lawrence SD, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. Ophthalmology. 2015 Oct;122(10):1987-2001.

809. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE. Ophthalmology. 2015 Oct;122(10):1967-75.

810. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Ophthalmology. 2015 Oct;122(10):1976-86.

811. Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results. Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA, Multicenter Uveitis Steroid Treatment Trial Research Group. Ophthalmology. 2015 Nov;122(11):2351-9.

812. Ocular Involvement in Systemic Lupus Erythematosus. Preble JM, Silpa-Archa S, Foster CS.  Curr Opin Ophthalmol. 2015 Nov;26(6):540-5.

813.  Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Multicenter Uveitis Steroid Treatment MUST Trial Research Group. Am J Ophthalmol. 2015 Dec;160(6):1133-1141.e9.

814. Freitas-Neto CA, Maghsoudlou A, Dhanireddy S, Payal A, Boonsopon S, Ratwatte MD, Foster CS. Outcome of Multiple Implants and Dissociation of Fluocinolone Acetonide Intravitreal Implant (Retisert) in a Series of 187 Consecutive Implants. Ocul Immunol Inflamm. 2015 Dec;23(6):425-9.

815. Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis. Sharma PK, Markov GT, Bajwa A, Foster CS. Retina. 2015 Dec;35(12):2641-6.

816. A Therapeutic Trial of Valganciclovir in Patients with Uveitis and Positive Epstein-Barr Virus Early Antigen D IgG Titers. Boonsopon S, Maghsoudlou A, Kombo NE, Foster CS. Eur J Ophthalmol. 2015 Dec 1;26(1):30-5.

817. Ocular manifestations in systemic lupus erythematosus. Silpa-Archa S, Lee JJ, Foster CS. Br J Ophthalmol. 2016 Jan;100(1):135-41.

818. Cataract Surgery Outcomes in Uveitis: The Multicenter Uveitis Steroid Treatment Trial. Sen HN, Abreu FM, Louis TA, Sugar EA, Altaweel MM, Elner SG, Holbrook JT, Jabs DA, Kim RY, Kempen JH; Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Ophthalmology. 2016 Jan;123(1):183-90.

819. Increased Submacular Choroidal Thickness in Active, Isolated, Extramacular Toxoplasmosis. Freitas-Neto CA, Cao JH, Oréfice JL, Costa RA, Oréfice F, Lee J, Payal A, Foster CS. Ophthalmology. 2016 Jan; 123(1):222-224.

820. The Ocular Immunology and Uveitis Foundation (OIUF) Preferred Practice Patterns of Uveitis Management. Foster CS, Kothari S, Anesi SD, Vitale AD, Chu D, Metzinger JL, Cerón O.  Surv Ophthalmol. 2016 Jan-Feb;61(1):1-17.

821. Short-Wavelength Automated Perimetry Parameters at Baseline and Following Remission in Patients with Birdshot Retinochoroidopathy. Maleki A, Swan RT, Silpa-Archa S, Preble J, He Y, Foster CS.  Am J Ophthalmol. 2016 Mar;163:83-92

822.  Treatment of Pediatric Uveitis with Adalimumab: The MERSI Experience.  Castiblanco C, Meese H, Foster CS. Journal of the American Association for Pediatric Ophthalmology and Strabismus, J AAPOS. 2016 Apr;20(2):145-7

823. Long-term side effects of glucocorticoids. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Expert Opinon on Drug Safety, Expert Opin Drug Saf. 2016 Apr;15(4):457-65.

824. Update on Ocular Cicatricial Pemphigoid and Emerging Treatments. Queisi M, Zein M, Lamba N, Meese H, Foster CS. Surv Ophthalmol. 2016 May-Jun;61(3):314-7.

825. Cocho L, Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Sainz-de-la-Maza M, Foster CS. Scleritis in patients with granulomatosis with polyangiitis (Wegener). British Journal of Ophthalmology 2016 July;100(8):1062-5

826. Multimodal Imaging Assisting the Early Diagnosis of Cat-Scratch Neuroretinitis.  Freitas-Neto CA, Oréfice F, Costa RA, Oréfice JL, Dhanireddy S, Maghsoudlou A, Foster CS. Seminars in Ophthalmology, 2016 August; 31(5):495-8

827. Scleritis Associated with Relapsing Polychondritis. Sainz-de-la-Maza M, Molina-Prat N, Gonzalez-Gonzalez LA, Doctor P, Tauber J, Foster CS. British Journal of Ophthalmology, 2016 August; 100(9):1290-4

828. Ocular morbidities of juvenile idiopathic arthritis-associated uveitis in adulthood: results from a tertiary center study. Oray M, Khachatryan N, Ebrahimiadib N, Abu Samra K, Lee S, Foster CS.  Graefes Arch Clin Exp Ophthalmol, 2016 September; 254(9):1841-9

829.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis. Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus Dryja, Andrew M. Wright, Irina Koroleva, Gerard Bruin, Christian Antoni, Zoe Draelos, Michael H. Gold, the Psoriasis Study Group, Patrick Durez, Paul P. Tak, Juan J. Gomez-Reino, the Rheumatoid Arthritis Study Group, C. Stephen Foster, Rosa Y. Kim, C. Michael Samson, Naomi S. Falk, David S. Chu, David Callanan, Quan Dong Nguyen, the Uveitis Study Group, Kristine Rose, Asifa Haider, Franco Di Padova1. Sci. Transl. Med., 2010 October 6;2(52):52ra72

830. Rituximab in the Treatment of Refractory Non-Infectious Scleritis. Cao JH, Oray M, Cocho L, Foster CS. American Journal of Ophthalmology. 2016

831. Adalimumab for Ocular Inflammation. Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombuth P, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Bussenblatt RB, Foster CS. Ocular Immunology and Inflammation. 2016 March 22; 25(3): 404-412

832. Birdshot Chorioretinitis Lesions on Indocyanine Green Angiography as an Indicator of Disease Activity. Cao JH, Silpa-Archa S, Freitas-Neto CA, Foster CS. Retina. 2016; 36(9):1751-1757

833. Remission of Intermediate Uveitis: Incidence and Predictive Factors. Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Payal A, Fitzgerald TD.   American Journal of Ophthalmology. 2016 April; 164:110-117

834. Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis J, Jabs DA, for the Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.  American Journal of Ophthalmology. 2016 April; 164: 29-36

835. Visual Outcome and Poor Prognostic Factors in Isolated Idiopathic Retinal Vasculitis. Maleki A, Cao JH, Silpa-Archa S, Foster CS. Retina. 2016; 36: 1979-1985

836. Interleukin-22 serum levels are elevated in active scleritis. Sainz-de-la-Maza M, Molins B, Mesquida M, Llorenc V, Zarranz-Ventura J, Sala-Puigdollers A, Matas J, Adan A, Foster CS. Acta Ophthalmologica. 2016; 94:e395-e399

837. Analysis of Three-dimensional choroidal volume with enhanced depth imaging findings in patients with birdshot retinochoroidopathy. Silpa-Archa S, Maleki A, Roohipoor R, Preble J, Foster CS. Retina. 2016; 36:1758-1766

838. Suelves AM, Lamba N, Meese HK, Foster CS, JM González-Martín; M Díaz-Llopis, Christen WM. Nuclear cataract as an early predictive factor for recalcitrant juvenile idiopathic arthritis-associated uveitis. Journal of the American Association for Pediatric Ophthalmology and Strabismus. 2016; 20:232-238

839. Infliximab after Boston Keratoprosthesis in Stevens-Johnson Syndrome: An Update. Robert MC, Črnej A, Shen LQ, Papaliodis GN, Dana R, Foster CS, Chodosh J, Dohlman CH. Ocular Immunology and Inflammation. 2017;25(3): 413-417

840. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Silpa-Archa S, Oray M, Preble JM, Foster CS. Acta Ophthalmologica. 2016; 94: e400-e406

841. Granulomatosis with Polyangiitis (Wegener’s disease): An Updated Review of Ocular Disease Manifestations. Kubaisi B, Abu Samra K, Foster CS. Intractable and Rare Disease Research. 2016; 5(2):61-69

842. Vogt-Koyanagi-Harada Syndrome: Perspectives for Immunogenetics, Multimodal Imaging and Therapeutic Options. Silpa Archa S, Preble JM, Foster CS.  Autoimmunity Reviews. 2016; 15: 809-819

843. Efficacy and Safety of intravenous immunoglobulin therapy in refractory uveitis. Sahawneh H, Maleki A, Foster CS.  2016; 1(1): 1-4

844. Successful Treatment Strategies in Granulomatosis with Polyangiitis associated Peripheral Ulcerative Keratitis. Ebrahimiadib N, Mdjtahedi BS, Roohipoor R, Anesi SD, Foster CS.  Cornea. 2016; 35(11): 1459-1465

845. Poor Prognostic factors in patients with birdshot retinochoroidopathy. Silpa-archa S, Lee JJ, Boonsopon S, Lizarraga M, Preble JP, Sujirarat D, Patel P, Foster CS. Retina. 2016; 36: 2220-2226

846. Moxifloxacin concentration and proteome analysis of aqueous humor in human uveitis associated with oral moxifloxacin therapy. Hinkle DM, Kruh-Garcia NA, Kruh JN, Broccardo C, Doctor P, Foster CS.  The Open Ophthalmology Journal. 2017; 11: 107-116

847. Selective Laser Trabeculoplasty in Controlled Uveitis with Steroid-Induced Glaucoma. Maleki A, Swan RT, Lasave AF, Ma L, Foster CS. Ophthalmology. 2016; 123(12): 2630-2632

848. Serpiginous Choroiditis. Ahmed AH, Kubaisi B, Foster CS.  JAMA Ophthalmology. 2017 April 1;135(4):e165495

849.  Risk of Ocular Hypertension in Adults with Noninfectious Uveitis. Daniel E, Pistilli M, Kothari S, Khachatryan N, Kaçmaz RO, Gangaputra SS, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Bhatt NP, Kempen JH. Ophthalmology. 2017 August; 124(8): 1196-1208

850. A review and update on orphan drugs for the treatment of noninfectious uveitis. You C, Sahawneh HF, Ma L, Kubaisi B, Schmidt A, Foster CS. Clinical Ophthalmology (Auckland, NZ). 2017;11:257-265

Previous 50   Next 50

  • Online Physician Forum

    Our Online Physician Forum is currently under development. Please check back periodically.
  • Twitter Feed